SEOUL (Reuters) – South Korea has reached a deal to buy 10 million doses of SK Bioscience’s coronavirus vaccine candidate, the Korea Disease Control and Prevention Agency (KDCA) said on Monday.
The South Korean vaccine developer is conducting a Phase 3 trial with the goal of securing formal approval for public distribution in the first half of 2023, the KDCA said.
(Reporting by Hyonhee Shin; Editing by Tom Hogue)
